0001661181-20-000006.txt : 20200424 0001661181-20-000006.hdr.sgml : 20200424 20200424071358 ACCESSION NUMBER: 0001661181-20-000006 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200121 FILED AS OF DATE: 20200424 DATE AS OF CHANGE: 20200424 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Montecalvo Antonio S. CENTRAL INDEX KEY: 0001759261 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37906 FILM NUMBER: 20812471 MAIL ADDRESS: STREET 1: C/O ORGANOGENESIS INC. STREET 2: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Organogenesis Holdings Inc. CENTRAL INDEX KEY: 0001661181 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 BUSINESS PHONE: 781-575-0775 MAIL ADDRESS: STREET 1: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 FORMER COMPANY: FORMER CONFORMED NAME: Avista Healthcare Public Acquisition Corp. DATE OF NAME CHANGE: 20151215 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2020-01-21 0001661181 Organogenesis Holdings Inc. ORGO 0001759261 Montecalvo Antonio S. C/O ORGANOGENESIS HOLDINGS INC. 85 DAN ROAD CANTON MA 02021 0 1 0 0 VP Health Policy & Contracting Class A Common Stock 2020-01-21 4 M 0 30450 1.70 A 38932 D Class A Common Stock 2020-04-22 4 A 0 24134 0 A 63066 D Stock Option (Right to Buy) 1.70 2020-01-21 4 M 0 30450 0 D 2020-02-22 Class A Common Stock 30450 0 D Stock Option (Right to Buy) 4.04 2020-04-22 4 A 0 158967 0 A 2030-04-22 Class A Common Stock 158967 158967 D Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning April 1, 2020. 100% of the shares subject to the option are fully vested and exercisable. The option becomes exercisable in equal annual installments over four years beginning April 1, 2020. /s/ Stacie S. Aarestad, Attorney-in-Fact 2020-04-24